How Do Hormones and Menopause Affect Bone Density?
Hormonal health is one of the foundational pillars of skeletal strength. The most important hormonal change during menopause is the fall in oestrogen, which accelerates bone remodelling and can cause bone breakdown to outpace bone formation.
This does not mean osteoporosis is inevitable. Instead, the menopausal transition offers a critical window to protect muscle mass, strengthen bones, review nutrition, and discuss hormonal or medical options. It also brings prevention to the forefront. Knowing that hormonal changes occur during perimenopause and menopause, it is vital to strengthen bones with weight-bearing exercises a few years in advance.
Furthermore, bone health is not simply a matter of calcium. It is influenced by hormones, protein, movement, digestion, micronutrients, medications, inflammation and the wider environment.
Bone is living tissue
Bone is continuously renewed through a process called bone remodelling.
Osteoclasts break down older bone.
Osteoblasts build new bone.
Osteocytes help sense mechanical loading and coordinate bone activity.
Oestrogen normally helps keep this process balanced by limiting excessive osteoclast activity and supporting the survival and function of bone-forming cells. When oestrogen levels fall, bone resorption increases and the skeleton can lose density more rapidly.
What happens during menopause?
Bone loss can begin during perimenopause, when hormone levels become more variable, and often accelerates around the final menstrual period. The rate varies between individuals and is influenced by:
Age at menopause.
Genetics and family history.
Baseline bone density.
Body weight.
Protein, calcium and mineral intake.
Vitamin D status.
Physical activity.
Smoking and alcohol.
Thyroid and parathyroid health.
Digestive absorption.
Medication use.
Previous fractures.
Exposure to heavy metals and micro- and nanoplastics.
The menopausal transition is therefore a period in which hormonal, metabolic, muscular and lifestyle changes may occur together.
Why oestrogen matters
Oestrogen helps regulate the balance between osteoclasts and osteoblasts. When oestrogen declines:
Osteoclast activity may increase.
Bone breakdown accelerates.
The remodelling cycle becomes less balanced.
Trabecular bone, particularly in the spine, can become more vulnerable.
Cortical bone at sites such as the hip may also deteriorate over time.
Fracture risk can increase even before osteoporosis is formally diagnosed.
The risk is not determined by oestrogen alone. A person with a relatively low bone density before menopause may be more vulnerable than someone with a higher baseline density, even if both experience a similar hormonal transition.
What is early menopause?
In UK clinical practice, early menopause generally means menopause before age 45. Premature ovarian insufficiency, or POI, refers to loss of ovarian function before age 40. It can involve intermittent ovarian activity, irregular periods, infertility and prolonged exposure to low oestrogen levels.
Early menopause and POI may result from:
Natural ovarian insufficiency.
Surgery involving the ovaries.
Chemotherapy or radiotherapy.
Certain autoimmune conditions.
Genetic factors.
Some infections or medical treatments.
Sometimes, no clear cause is found.
Because oestrogen protection is lost earlier and for longer, early menopause is a recognised risk factor for osteoporosis and cardiovascular disease.
Why early menopause matters for bones
A person who experiences menopause at 40 may spend a decade or more with lower oestrogen levels than someone whose menopause occurs at the average age. This can lead to a longer period of increased bone resorption
Assessment may be particularly important when early menopause occurs alongside:
Low body weight.
A history of eating difficulties or calorie restriction (crash dieting)
Amenorrhoea before menopause.
Coeliac disease or inflammatory bowel disease.
Long-term corticosteroid use.
Previous fragility fracture.
Strong family history.
Smoking or high alcohol intake.
Low vitamin D or dietary calcium intake.
HRT and bone protection
Hormone replacement therapy can reduce menopausal symptoms and help maintain bone strength.
For premature ovarian insufficiency, professional guidance generally recommends hormone replacement until around the natural age of menopause, usually approximately 50–51, unless there is a contraindication. This is because replacement aims to restore hormones that would normally still be present, supporting bone and cardiovascular health.
HRT is not suitable for everyone. Decisions should consider:
Personal and family medical history.
Breast and endometrial cancer risk.
Blood-clot history.
Cardiovascular disease.
Migraine.
Liver disease.
Whether the uterus is present.
Route and dose of treatment.
Age and timing of menopause.
HRT should not be started, stopped or altered without appropriate clinical advice. It is also not a replacement for resistance exercise, sufficient nutrition, or osteoporosis treatment when indicated.
Other hormonal conditions that affect bone
Oestrogen decline is central to menopause-related bone loss, but other endocrine factors may also weaken the skeleton.
— Thyroid excess
Untreated hyperthyroidism can accelerate bone turnover. Excessive thyroid-hormone replacement may also contribute to bone loss, particularly in postmenopausal women.
— Low reproductive hormones
Amenorrhoea associated with under-eating, excessive exercise, stress or hypothalamic dysfunction can reduce oestrogen exposure and compromise bone health. This can occur before the natural menopause.
— Parathyroid disorders
Excess parathyroid hormone can increase calcium release from bone and requires medical assessment.
— Adrenal and other endocrine disorders
Cushing’s syndrome, some pituitary disorders and other hormonal conditions can affect bone metabolism. Persistent symptoms, unexplained fractures or unusual laboratory findings warrant medical investigation rather than a supplement-only approach.
What is the role of vitamin K?
Vitamin K helps activate several proteins involved in bone biology, including osteocalcin. In biochemical terms, it supports the carboxylation of osteocalcin, helping the protein bind calcium within the bone matrix. While vitamin D helps your body absorb calcium from your food, vitamin K2 acts as a chaperone, guiding calcium to the bones and teeth while keeping it out of the soft tissues and arteries.
Food sources of Vitamin K:
Brassicas (e.g., kale, spinach, spring greens, broccoli, cabbage, etc.).
Herbs.
Some fermented foods.
Certain animal foods, depending on the form of vitamin K.
A varied diet usually provides vitamin K for most people.
Does vitamin K supplementation prevent osteoporosis?
The evidence is promising but not definitive.
Recent meta-analyses suggest that vitamin K, particularly vitamin K2, may improve bone mineral density or bone-metabolism markers. However, evidence for fracture prevention remains uncertain, and vitamin K cannot be considered a standalone treatment for osteoporosis; it should be used alongside adequate calcium and vitamin D intake, protein, or exercise.
Note: People taking warfarin or other vitamin K-sensitive anticoagulants must seek medical advice before supplementing.
How does weight training help?
Resistance training applies mechanical load to muscles, tendons and bones. Bone cells respond to strain and loading signals by modifying bone formation and remodelling.
Weight training can help by:
Stimulating bone adaptation
Maintaining or increasing muscle mass
Improving strength
Supporting posture and spinal stability
Improving balance
Reducing the risk of falls
Helping maintain independence
Supporting metabolic and hormonal health.
NICE advises women with menopause to maintain muscle mass and strength through physical activity, and the 2024 UK osteoporosis guideline recommends regular weight-bearing and muscle-strengthening exercise tailored to individual ability. Combined exercise programmes can help reduce bone loss at the femoral neck and lumbar spine in postmenopausal women.
— A progressive approach
A suitable programme may include:
Squats or sit-to-stand exercises
Lunges or supported step-ups
Hip-hinge movements
Rows and pulling exercises
Pressing exercises
Carrying weights
Calf raises
Spinal extension work
Balance training
Begin with a safe level and progress gradually. People with established osteoporosis, vertebral fractures, severe pain or high fracture risk may need exercise prescribed by a physiotherapist or appropriately qualified professional.
— Is walking enough?
Walking is valuable for cardiovascular health, mood, and general mobility, but it may not provide enough resistance to maintain or increase bone density on its own. A comprehensive programme usually combines weight-bearing activity with progressive resistance and balance work.
High-impact exercise is not appropriate for everyone. It may need to be modified in people with osteoporosis, vertebral fractures, joint disease or significant fall risk.
Nutrition during menopause
Hormonal changes can coincide with altered appetite, sleep disruption, changes in body composition, and reduced muscle mass. A bone-supportive eating pattern should provide:
Adequate total energy.
- Protein distributed across the day.
- Calcium-rich foods.
- Vitamin D from appropriate sources.
- Magnesium-rich foods.
- Vitamin K-rich vegetables.
- Fruit and vegetables.
- Healthy fats.
- Sufficient carbohydrates for activity and recovery.
Calcium-rich foods may include yoghurt, milk, fortified plant drinks, calcium-set tofu, canned fish with bones, leafy greens and some mineral waters.
The current UK osteoporosis guideline recommends a balanced, nutrient-rich diet, a minimum daily calcium intake of 700 mg for adults, and vitamin D supplementation of at least 800 IU daily when vitamin D insufficiency or risk factors are identified.[13]
The correct intake depends on dietary pattern, absorption, age, kidney function, medications and clinical status. More is not always better.
The gut–bone connection
Menopause-related bone loss can be exacerbated when digestion or absorption is impaired or by certain conditions, such as:
Coeliac disease
Inflammatory bowel disease
Chronic diarrhoea
Pancreatic or enzymatic insufficiency
Previous gastrointestinal surgery
Long-term restrictive dieting
Low protein intake
A person may consume apparently “healthy” foods while still failing to absorb sufficient calcium, vitamin D, protein or other nutrients. Persistent digestive symptoms, anaemia, low body weight or unexplained osteopenia deserve investigation.
This is where Nutrunity’s focus on the gut–brain–liver axis and naturopathic nutrition can add value: the goal is not merely to recommend supplements, but to understand whether the person can digest, absorb and use the nutrients required for skeletal health.
Heavy metals and endocrine disruption
Heavy metals such as lead and cadmium have been associated with lower bone mineral density and higher risk of osteopenia or osteoporosis. They may affect bone through oxidative stress, inflammation, endocrine disruption, renal effects, and interference with bone cell activity.
Some heavy metals can also accumulate in bone, replacing calcium, and remain there for long periods. However, a positive exposure does not automatically prove that it caused an individual’s osteoporosis.
A clinically responsible approach should:
Take an exposure history
Identify occupational, environmental and dietary sources
Use validated testing only when clinically justified
Avoid indiscriminate chelation or “detox” protocols
Treat established osteoporosis through standard evidence-based care.
Micro- and nanoplastics
Microplastics and nanoplastics are emerging environmental exposures that may have endocrine, inflammatory and oxidative effects. Recent reviews discuss possible effects on osteoblasts, osteoclasts, bone remodelling and musculoskeletal health.
At present, human evidence is not strong enough to say that everyday microplastic exposure causes osteoporosis or to quantify an individual’s fracture risk.
Reasonable exposure-reduction measures include:
Avoiding heating food in plastic containers
Using glass or stainless steel for hot food and drinks
Reducing reliance on single-use bottled water where safe alternatives exist
Choosing fresh or minimally packaged food where practical
Avoiding unnecessary plastic contact with hot, oily foods
Maintaining good ventilation when working with plastics or synthetic dusts (e.g., hoovering, tumble drying, etc.).
A Nutrunity menopause bone-health framework
— Assess
Age at menopause.
Menstrual changes and symptoms.
HRT or contraceptive use.
Fracture history.
Family history.
Weight and dieting history.
Digestive symptoms.
Protein, calcium and vitamin D intake.
Thyroid and other endocrine history.
Exercise and falls risk.
Medication and environmental exposure history.
— Nourish
Build meals around:
Adequate protein.
Calcium-rich foods.
Colourful, antioxidant-rich vegetables and fruits.
Vitamin K-rich greens.
Fibre and gut-supportive foods.
Healthy fats.
Meeting energy requirements.
— Strengthen
Introduce progressive resistance, weight-bearing activity, mobility and balance work at an appropriate level.
— Coordinate
Where indicated, work with GP, menopause specialist, endocrinologist, physiotherapist or osteoporosis service. Nutrunity’s integrative approach will complement all these treatments with a fully comprehensive plan.
— Monitor
Strength.
Balance.
Falls.
Menopausal symptoms.
Dietary adequacy.
Weight and muscle changes.
Relevant blood tests.
Bone mineral density when clinically indicated.
When to seek medical advice
Arrange medical assessment if you have:
A fracture after a minor fall.
Height loss or a stooped posture.
Menopause before age 45.
No periods for several months before age 40.
Long-term steroid treatment.
Unexplained weight loss.
Coeliac disease or inflammatory bowel disease.
Recurrent stress fractures.
Significant thyroid symptoms.
Known osteopenia with additional risk factors.
A strong family history of hip fracture.
Do not supplement with vitamin K, calcium, collagen or other supplements to treat established osteoporosis without appropriate clinical assessment.
Final perspective
Menopause-related bone loss is driven primarily by declining oestrogen and the resulting increase in bone remodelling and resorption. Early menopause and premature ovarian insufficiency deserve particular attention because bones are exposed to low oestrogen for longer.
Vitamin K contributes to bone protein activation, but current evidence does not justify treating it as a standalone osteoporosis therapy. Resistance training is one of the most valuable practical interventions because it supports bone loading, muscle strength, balance, and independence.
At Nutrunity, the most effective approach is comprehensive: assess hormonal timing, nourish the skeleton, protect muscle, support digestion, investigate relevant endocrine issues, reduce avoidable exposures, and coordinate with appropriate medical care.
Strong bones are built through consistent, informed action — not one mineral, one supplement or one isolated test.
Sources
Royal Osteoporosis Society. (2025). Hormone replacement therapy (HRT). Available: https://theros.org.uk/information-and-support/treatments-and-medicines/a-to-z-list-of-medicines/hormone-replacement-therapy-hrt
NICE. (2026). Menopause: identification and management. Available: https://www.nice.org.uk/guidance/ng23/resources/menopause-identification-and-management-pdf-1837330217413
NHS. (2025). Osteoporosis - Treatment. Available: https://www.nhs.uk/conditions/osteoporosis/treatment
British Menopause Society. (2024). Premature ovarian insufficiency - https://thebms.org.uk/publications/consensus-statements/premature-ovarian-insufficiency
References
Fusaro, M., Cianciolo, G., Brandi, ML. et al. (2020). Vitamin K and osteoporosis. Nutrients. 12(12), 3625. doi:10.3390/nu12123625
Gregson, CL., Armstrong, DJ., Avgerinou, C. et al. (2025). National Osteoporosis Guideline Group (NOGG). The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Archives in Osteoporosis. 20(1), 119. doi:10.1007/s11657-025-01588-3
Hu, L., Ji, J., Li, D. et al. (2021). The combined effect of vitamin K and calcium on bone mineral density in humans: A meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 16, 592. doi:10.1186/s13018-021-02728-4
Jalili, C., Kazemi, M., Taheri, E. et al. (2020). Exposure to heavy metals and the risk of osteopenia or osteoporosis: A systematic review and meta-analysis. Osteoporosis International. 31(9), pp. 1671-1682. doi:10.1007/s00198-020-05429-6
Ju, C., Dong, H., Liu, R. et al. (2026). Environmental micro-nanoplastics and musculoskeletal disorders: Current research and insights. International Journal of Nanomedicine. 21, 606793. doi:10.2147/IJN.S606793
Lim, HS., Lee, HH., Kim, TH. et al. (2016). Relationship between heavy metal exposure and bone mineral density in Korean adults. Journal of Bone Metabolism. 23(4), pp. 223-2231. doi:10.11005/jbm.2016.23.4.223
Ma, ML., Ma, ZJ., He, YL. et al. (2022). Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health. 10, 979649. doi:10.3389/fpubh.2022.979649
Pelepenko, LE., de Oliveira, MC., Masaro, DA. et al. (2025). Effects of microplastics on the bones: A comprehensive review. Osteoporosis International. 2025 Aug;36(8):1327-1345. doi:10.1007/s00198-025-07580-4
Salma., Ahmad, SS., Karim, S. et al. (2022). Effect of vitamin K on bone mineral density and fracture risk in adults: Systematic review and meta-analysis. Biomedicines. 10(5), 1048. doi:10.3390/biomedicines10051048
Xie, C., Gong, J., Zheng, C. et al. (2024). Effects of vitamin K supplementation on bone mineral density at different sites and bone metabolism in the middle-aged and elderly population. Bone Joint Research. 13(12), pp. 750-763. doi:10.1302/2046-3758.1312.BJR-2024-0053.R1
Zhang, Z., Li, Y., Li, J. et al. (2025). The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: A systematic review and meta-analysis. Frontiers in Endocrinology (Lausanne). 16, 1703116. doi:10.3389/fendo.2025.1703116